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We describe a Klebsiella oxytoca infection outbreak in a renal transplant unit that involved seven patients. All
strains belonged to a single pulsed-field gel electrophoresis pattern and were resistant to amoxicillin-clavu-
lanate, cefuroxime, piperacillin-tazobactam, and aztreonam but susceptible to ceftriaxone, ceftazidime,
cefepime, and imipenem. Chromosomal -lactamase hyperproduction was caused by a point mutation in the
blaOXY-2 gene promoter region.
Klebsiella oxytoca is an opportunistic pathogen responsible
for causing health care-associated infections (14, 15, 17). These
species possess chromosomal genes encoding -lactamases
that are constitutively expressed at low levels and that confer
resistance to amino- and carboxypenicillins but not to other
-lactams (4). K. oxytoca -lactamases were initially divided
into the two main groups OXY-1 and OXY-2, which possessed
distinct -lactam hydrolytic profiles (11, 12). Recently, other
OXY-type -lactamases (OXY-3 to OXY-6) have been re-
ported among K. oxytoca isolates (6). Distinct point mutations
in the 35 and 10 promoter regions of these -lactamase
genes have been pointed out as a reason for OXY hyperpro-
duction in 10 to 20% of K. oxytoca isolates and led to a broader
spectrum of -lactam resistance (10, 13).
Susceptibility to bacterial infection in renal transplantation
recipients is related directly to the level and duration of the
pharmacological immunosuppression. Bacterial urinary tract
infections are frequently associated with early onset chronic
rejection and may lead to reduced transplantation survival (8).
K. oxytoca infection outbreaks have been documented in
multiple settings (4, 15, 18, 19, 21). However, K. oxytoca infec-
tion outbreaks in transplantation units have not yet been re-
ported. The aim of this study was to evaluate the antimicrobial
susceptibility profiles, the genetic relatedness, and the mecha-
nisms of -lactam resistance among clinical isolates of K. oxy-
toca that caused health care-associated infections in a renal
transplantation unit of a teaching hospital located in Buenos
Aires, Argentina.
Seven K. oxytoca strains were isolated from the urine, peri-
toneal fluid, and central venous catheters of renal and renal-
pancreas transplantation patients hospitalized at the transplan-
tation unit of the University Hospital, CEMIC, between March
and August of 2005. According to an epidemiological investi-
gation, the index case was a renal transplantation patient who
developed a urinary tract infection caused by this strain during
the hospitalization period. The outbreak of infection involved
a total of seven patients (one isolate per patient). Horizontal
transmission was suspected because at that time, the transplan-
tation unit was located in a shared facility without individual
rooms, and all patients were attended by a common group of
health care workers.
The isolates were associated with infection and were iden-
tified by conventional methods (5). Antimicrobial susceptibility
testing was performed by using the Clinical and Laboratory
Standards Institute (CLSI) broth microdilution method and
interpreted according to CLSI breakpoints (CLSI, 2006).
Quality control was performed by testing Escherichia coli
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. All
quality control results were within published MIC ranges
(CLSI, 2006) (2, 3). Pulsed-field gel electrophoresis (PFGE)
was performed using the restriction endonuclease SpeI as pre-
viously described (16). Analysis of PFGE patterns was per-
formed by visual inspection of photographs of ethidium bro-
mide-stained gels. The isolates were classified according to the
criteria described by Tenover et al. (20).
Detection of the blaOXY group genes and promoter regions
was carried out by PCR, followed by DNA sequencing. PCR
was performed under standard conditions, using the primers
OXY-F (5-GATTTCACAAAGCGCTCGGC-3) and OXY-R
(5-CCTGCTGCGGCTGGGTAAAA-3), designed based on
the nucleotide sequences of the blaOXY-1 and blaOXY-2 genes
available at GenBank, under accession numbers Z30177 and
Z49084, respectively. PCR products were analyzed by electro-
phoresis in 1.0% agarose gels and were sequenced on both
strands by using an ABI Prism 377 sequencer unit. The nucle-
otide sequences and deduced amino acid sequences were an-
alyzed by using Lasergene software (DNAStar, Madison, WI).
The sequences obtained were compared to sequences available
at http://www.ebi.ac.uk/fasta33/.
The outer membrane proteins of the isolates were studied
according to the method described by Filip et al. (7). Wild-type
K. oxytoca strains susceptible to penicillins and broad-spectrum
cephalosporins were included as control strains.
The antimicrobial susceptibility profiles of the K. oxytoca strains
studied are presented in Table 1. The seven K. oxytoca strains
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were resistant to piperacillin, piperacillin-tazobactam, amoxicillin-
clavulanic acid, cephalothin, cefuroxime, and aztreonam but were
susceptible to ceftriaxone, ceftazidime, cefepime, and imipenem.
A single isolate was resistant to cefoxitin (MIC, 32 g/ml). No
plasmids were found by phenotypic and molecular analyses.
Seven K. oxytoca strains showed a unique PFGE pattern (pattern
A), as shown in Fig. 1. The presence of the blaOXY-2 gene was
detected in all strains. The blaOXY-2 promoter sequence region of
clone A was P (35[TTGTCA]; 10[GATAAT]), which dif-
fered by one base (underlined) from the weak promoter,
P (35[TTGTCA]; 10[GATAGT]), present in the K. oxytoca
wild type carrying blaOXY-2. The outer membrane profiles were
identical among the K. oxytoca isolates studied, except for the
cefoxitin-resistant strain, which exhibited reduced expression of
the 36-kDa outer membrane protein on a sodium dodecyl sulfate-
polyacrylamide gel.
We describe an outbreak of K. oxytoca infection among
transplantation patients (hospitalized in a single institution),
caused by an isolate that overproduces OXY-2 due to a mu-
tation in the blaOXY-2 promoter region. OXY -lactamases are
chromosomally encoded and are usually synthesized at low
levels, conferring resistance to amino- and carboxypenicillins.
Overproduction of such enzymes results from a mutation in the
-lactamase gene promoter, enhancing the hydrolytic substrate
profile and conferring resistance to penicillins and some ex-
tended-spectrum -lactams, especially aztreonam (9). In con-
trast, these strains are susceptible to ceftriaxone, ceftazidime,
and cefepime, as observed with our study. This feature helps to
distinguish OXY-type overproducers from K. oxytoca isolates
that harbor plasmid-encoded extended-spectrum -lactamases
(4, 6). In spite of being encoded by chromosomal DNA, this
group of enzymes has been grouped with the extended-spec-
trum -lactamases in the 2be class of the classification by Bush
et al., due to the substrate profiles and inhibition patterns
found by clavulanic acid (1).
OXY-2-producing K. oxytoca strains are more commonly (53
to 74%) isolated from clinical specimens and are usually more
resistant than OXY-1 producers. The substitution of guanine
with adenine in the 10 blaOXY-2 promoter region, as ob-
served with this study, has already been described to enhance
OXY-2 expression about 13-fold in K. oxytoca strain SL911 (9,
13). This is the probable reason for the -lactam susceptibility
profile displayed by clone A.
The outbreak of infection was controlled by an enhancement
of standard biosafety precautions (i.e., hand-washing practice)
through an educational program and contact isolation proce-
dures. All the outbreak control procedures were supervised
directly by the infection control department of the institution.
In summary, a unique clone of K. oxytoca was responsible for
causing infections in a renal transplantation unit, suggesting
that the patients might have acquired this clone from a com-
mon source. These isolates displayed enhanced resistance to
-lactams, including cefuroxime and aztreonam, which was
attributed to a single base change in the 10 consensus se-
quence of the promoter. In addition, it is possible that cefoxitin
resistance in one of these strains was caused by the diminished
expression of the 36-kDa outer membrane protein. Epidemi-
ologic surveillance of transplantation units is of major impor-
tance to the prevention and early detection of outbreaks
caused by multidrug-resistant bacteria.
TABLE 1. Antimicrobial susceptibility profiles of wild-type K. oxytoca and K. oxytoca OXY-2 hyperproducer strains evaluated in this study
Isolate
MIC (g/ml) of the indicated drugs to K. oxytoca isolatesa
AMK GEN AMP SAM AMC FEP CRO CAZ CXM CEF CIP MEZ TZP PIP TIM CTT SXT ATM IPM MER
7 16 8 16 16/8 16/8 1 1 2 16 16 2 64 64/2 64 64/2 4 2/38 256 0.25 0.25
6 8 4 16 16/8 16/8 1 2 2 16 16 2 64 64/4 64 64/2 8 2/38 256 0.5 0.25
5 16 8 16 16/8 16/8 2 8 2 16 16 8 64 64/4 64 64/4 32 2/38 256 0.25 0.25
4 16 1 16 16/8 16/8 1 2 1 16 16 2 64 64/4 64 64/4 4 2/38 256 0.5 0.25
3 2 4 16 16/8 16/8 1 2 1 16 16 2 64 64/4 64 64/4 4 2/38 256 0.5 0.25
2 16 4 16 16/8 16/8 1 1 2 16 16 2 64 64/4 64 64/4 4 2/38 256 0.5 0.25
1 8 2 16 16/8 16/8 1 1 2 16 16 2 64 64/4 64 64/4 4 2/38 256 0.5 0.25
a MIC values were determined by broth microdilution technique (3). AMK, amikacin; AMC, amoxicillin-clavulanic acid; SAM, ampicillin-sulbactam; AMP,
ampicillin; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; CEF, cephalothin; CIP, ciprofloxacin; GEN, gentamicin; IPM, imipenem; MER,
meropenem; ATM, aztreonam; MEZ, mezlocillin; TZP, piperacillin-tazobactam; PIP, piperacillin; TIM, ticarcillin-clavulanic acid; CTT, cefoxitin; SXT, trimethoprim-
sulfamethoxazole.
FIG. 1. PFGE patterns of SpeI-digested chromosomal DNA restric-
tion fragments from K. oxytoca isolates resolved in 1% SeaKem Gold
agarose. Lanes 1 and 11, molecular weight standards of lambda ladder.
Lane 2, strain 1 (PFGE pattern A); lane 3, strain X (quality control
strain); lane 4, strain 2 (PFGE pattern A); lane 5, strain 3 (PFGE pattern
A); lane 6, strain 4 (PFGE pattern A); lane 7, strain 5 (PFGE pattern A);
lane 8, strain 6 (PFGE pattern A); lane 9, strain 7 (PFGE pattern A); and
lane 10, strain U (quality control strain).
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